Welcome to the Next Generation Cardiovascular Drug Development Summit
Executing Cell & Gene Therapy for Cardiac Regeneration
Join 80+ industry experts and academia in advancing towards novel cardiovascular disease therapeutics by:
- Navigating the safety vs toxicity hurdle to achieve success in clinical trials by agreeing on a standardized approach for dose escalation and endpoints with the FDA
- Discovering novel AAVs with improved cardiac to liver transduction using capsid engineering with Tenaya Therapeutics
- Understanding the genetic aspects of cardiomyopathy and deliberating current and future models to better recapitulate human cardiovascular disease with BlueRock Therapeutics
- Delving into the opportunities and challenges for genomics to enhance biomarker-guided treatment strategies in the prevention and treatment of cardiometabolic disease with Novartis Institutes of Biomedical Research
'Great opportunity to network and hear updates on innovative gene and cell therapy approaches in CV drug development'
- Denise Yates, Executive Director, Biomarker Development Cardiovascular and Metabolism Therapeutic Area Head
Learn From a World-Class Speaker Faculty, Included:
Denise Yates
Executive Director, Biomarker Development Cardiovascular & Metabolism Therapeutic Area Head
Novartis Institutes of Biomedical Research
Other Events in the Series
